促性腺激素释放激素激动剂治疗女童性早熟的不良反应探析  

Discussion on adverse reactions of gonadotropin releasing hormone agonists as the treatment of precocious puberty in girls

作　　者：黄蓉(综述)[1] 俞建(审校)[1] 

机构地区：[1]复旦大学附属儿科医院,上海201102

出　　处：《国际儿科学杂志》2010年第4期432-435,共4页International Journal of Pediatrics

摘　　要：促性腺激素释放激素激动剂（gonadotropin releasing hormone agonist,GnRHa）是目前临床广泛应用的相对安全的性早熟治疗药物.患儿在停药后可以正常月经来潮、怀孕、生育.GnRHa不会降低青春期后的子宫体积,停药后的黄体生成素、卵泡刺激素及性激素水平可恢复至接近或超过停药前水平.研究提示促性腺激素释放激素拟似物可能会增加罹患雄激素过多症及多囊卵巢综合征的风险,但尚缺乏较高等级的证据.现有的研究不能提供充分证据表明GnRHa对骨矿物质密度有显著和不可逆的负面影响.GnRHa可能具有增加体质量指数（BMI）的不良反应,亦有研究表明GnRHa有助于降低BMI,或不会增加BMI.Gonadotropin releasing hormone agonists（GnRHa）are the relatively safe drugs widely used in clinic to treat precocious puberty.After therapy withdrawal,the patients would have normal menstrual onset,gestation and fertility.GnRHa didn＇t degrade uterus volume of post puberty.After cessation of GnRHa,luteinizing hormone,follicle stimulating hormone and sex hormone levels would return to those before therapy,or even exceed them.Some researches suggested that gonadotropin releasing hormone analogue might increase the risk of androgen excess and polycystic ovary syndrome.The researches apply no sufficient evidences to show that GnRHa had significant and irreversible negative influences on bone mineral density.GnRHa might have the side effect of increasing body mass index（BMI）.However,researches also showed that GnRHa was helpful to decrease BMI,or not to increase it.

关 键 词：促性腺激素释放激素激动剂 促性腺激素释放激素拟似物 性早熟 不良反应 

分 类 号：R711.71[医药卫生—妇产科学]